Title and bibliographic details
The PubMed entry is for a randomized clinical trial titled Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma. The article appears in NEJM Evidence (NEJM Evid) with citation details 2026 Sep;5(9):EVIDoa2500278 and electronic publication on 2026 Aug 25. The PubMed identifier is PMID 42640170 and the DOI is 10.1056/EVIDoa2500278.
Author list and affiliations
The published record lists Wang-Zhong Li as first author among a multi-author team. Coauthors include Shu-Hui Lv, Shui-Qing He, Xing Lv, Lin Wang, Ya-Hui Yu, Wei-Xiong Xia, Yan-Fang Ye, Dan Hu, Wei-Xin Bei, Nian Lu, Meng-Yun Shi, Liang-Ru Ke, Hu Liang, Chuan-Run Zhang, Ze-Yu Zhao, Han-Xiong Zhang, Li-Hua Tong, Wen Yang, Wu-Bing Tang, Tai-Ze Yuan, Xiang Guo, Chang-Qing Xie, Guo-Ying Liu, and Yan-Qun Xiang.
Affiliations reported on the PubMed record include:
- Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China
- Department of Radiation Oncology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Department of Radiation Oncology, Zhujiang Hospital of Southern Medical University, Guangzhou, China
- Clinical Research Design Division, Sun Yat-Sen Memorial Hospital, Guangzhou, China
- Department of Radiation Oncology, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, China
- Department of Medical Imaging, Sun Yat-sen University Cancer Center, Guangzhou, China
- Cancer Center, School of Medicine, Nanhai People's Hospital, Sixth Affiliated Hospital of South China University of Technology, Foshan, China
- Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, China
- Frederick Health Hematology Oncology, James M. Stockman Cancer Institute, Frederick, MD, USA
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation; Department of Radiation Oncology, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
These affiliations indicate a multi-center collaboration across institutional cancer and oncology divisions in China with at least one listed U.S. affiliation.
Article classification and publication metadata
PubMed classifies the item as a Randomized Controlled Trial. The entry presents the journal name (NEJM Evid), volume and issue information (5[9]), and the electronic publication date. The DOI and PMID are provided for reference and retrieval.
What is reported on PubMed
From the provided PubMed source content we can confirm the following factual elements:
- Study title and focus: Induction Paclitaxel-Cisplatin-Capecitabine in nasopharyngeal carcinoma.
- Publication outlet: NEJM Evidence (NEJM Evid).
- Publication metadata: Epub date (2026 Aug 25), issue (2026 Sep;5[9]:EVIDoa2500278), DOI 10.1056/EVIDoa2500278, PMID 42640170.
- Study classification on PubMed: Randomized Controlled Trial.
- Full author list and institutional affiliations are recorded on the PubMed page.
What is not reported in the provided source
The PubMed page content supplied here is limited to bibliographic, navigation, and author-affiliation metadata. The following critical elements were not included in the provided source text and therefore cannot be summarized or interpreted:
- Trial design specifics (randomization method, control/comparator, blinding status).
- Eligibility criteria and baseline patient characteristics (stage, prior treatment, performance status).
- Sample size and enrollment dates.
- Primary and secondary endpoints (efficacy and safety endpoints), definitions, and timepoints.
- Numerical results for efficacy (response rates, survival outcomes such as progression-free survival or overall survival) or toxicity (grade 3–5 adverse events, treatment-related discontinuations).
- Statistical analysis methods and significance testing outcomes.
- Authors’ conclusions, clinical interpretations, or guideline implications.
Because these elements are absent from the supplied source JINA body, any inference about outcomes, magnitude of benefit, or safety profile would require consulting the full article or an abstract that includes trial results.
Implications and next steps for readers
The PubMed record confirms that a randomized trial of induction paclitaxel-cisplatin-capecitabine in nasopharyngeal carcinoma has been published and is retrievable via DOI or PMID. For clinicians, researchers, or guideline developers who need to evaluate the trial’s clinical impact, the next steps are:
- Retrieve and read the full article in NEJM Evidence via the DOI or journal website to examine trial methods, results, and authors’ conclusions.
- Review the abstract and supplementary materials for detailed efficacy and safety data, including absolute event rates and confidence intervals.
- Assess external validity by comparing eligibility criteria and baseline characteristics with the intended patient population.
- Consider contacting the corresponding author or institutional sources if additional clarification of methods or data sharing is required.
Note: This summary is limited to the bibliographic and metadata elements present in the provided PubMed source text. Study methods, outcomes, and conclusions were not reported in that source and therefore are not included here.